PATENT CLAIM ANALYSIS

Application Number: 15987449
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "215000"]

Abstract:
The present invention relates to 5-HT 6  receptor antagonists for the treatment of Alzheimer's disease where the Alzheimer's disease patient carries one or two ApoE4 alleles comprising administering an effective dose of a 5-HT 6  receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.

Claim (Index 33):
A method of treating Alzheimer's disease in a subject in need thereof comprising administering a dose of 60 mg/day of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine or a pharmaceutically acceptable salt thereof, wherein the subject carries one or two APOE4 alleles, and wherein the subject is being treated with an acetylcholinesterase inhibitor selected from the group consisting of donepezil or a pharmaceutically acceptable salt thereof, rivastigmine or a pharmaceutically acceptable salt thereof, or galantamine or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.35135
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15194947', '15696880', '15084712', '14021033', '15323426']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8010354208695429
- 35 USC 102 Novelty (BERT): 0.5411312502085703
- Combined Prediction Score: 0.7750450038034458
- Mean Citation Score: 380.656292
- Max Citation Score: 392.42154
- Similarity Product: 341.069572709502

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test